Last checked at 12 Apr 2023 10:00
12 April 2023 |
|
ALLIANCE PHARMA PLC
("Alliance" or the "Group")
Annual Report & Accounts and Notice of AGM
Alliance Pharma plc (AIM: APH), the international healthcare group, announces that the following documents are now available on the Group's website, www.alliancepharmaceuticals.com:
· The Annual Report & Accounts for the year ended 31 December 2022
· The Notice of the 2023 Annual General Meeting ("AGM"), which will be held at 09.00 am on 25th May 2023.
Printed copies of both documents have been mailed to those shareholders who have opted out of receiving electronic communications from the Group.
Printed copies of the documents are also available by contacting Buchanan by email at alliancepharma@buchanan.uk.com or by telephoning Buchanan on 020 7466 5000.
For further information:
Alliance Pharma plc | + 44 (0)1249 466966 |
Cora McCallum, Head of Investor Relations & Corporate Communications | + 44 (0)1249 705168 |
ir@allianceph.com | |
Buchanan | + 44 (0)20 7466 5000 |
Mark Court / Sophie Wills / Hannah Ratcliff | |
alliancepharma@buchanan.uk.com | |
Numis Securities Limited | + 44 (0)20 7260 1000 |
Nominated Adviser: Freddie Barnfield / Duncan Monteith | |
Corporate Broking: James Black | |
Investec Bank plc | + 44 (0)20 7597 5970 |
Corporate Broking: Patrick Robb |
About Alliance
Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.
We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions.
Headquartered in the UK, the Group employs around 285 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands. For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com